Plasma plasminogen activator inhibitor-1 as a predictive marker of type 2 diabetic nephropathy in Egyptian patients
Background The study investigates the relationship between Plasminogen activator inhibitor-1 (PAI-1) levels and the progression of diabetic nephropathy (DN). The fibrinolytic system is impaired in type 2 diabetes mellitus (DM), leading to elevated PAI-1 levels, increasing the potential for renal fib...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-07-01
|
| Series: | Al-Azhar Assiut Medical Journal |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/azmj.azmj_22_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background
The study investigates the relationship between Plasminogen activator inhibitor-1 (PAI-1) levels and the progression of diabetic nephropathy (DN). The fibrinolytic system is impaired in type 2 diabetes mellitus (DM), leading to elevated PAI-1 levels, increasing the potential for renal fibrosis and worsening nephropathy.
Patients and methods
The research involved 196 type 2 DM patients and 50 healthy control individuals divided into four groups based on Urinary albumin excretion (UAE).
Results
The diabetic group had significantly higher PAI-1 levels than the control group. The study also found that diabetic patients with macroalbuminuria had higher PAI-1 levels than the control group. Patients with higher UAE and PAI-1 levels had significantly higher serum creatinine concentrations. The study found a significant negative link with creatinine clearance and a significant positive correlation between PAI-1 and serum creatinine and 24-h urine albumin in terms of PAI-1.
Conclusions
There was a notable positive association with the 24-h UAE, suggesting that increases in PAI-1 were linked to a decline in renal function. |
|---|---|
| ISSN: | 1687-1693 |